STAT+: Medicare chief says TrumpRx is meant to be narrow in scope

Summary: Medicare boss Chris Klomp recently spoke about the new "TrumpRx" drug program. Even though President Trump called the program a huge, "transformative" change, Klomp says it is actually just a small, cash-pay tool and not a total fix for high prescription prices.

In other medical news, Novo Nordisk just got approval for a stronger dose of its weight-loss drug, Wegovy, to help win back customers. Also, the U.K. is taking a second look at two Alzheimer's drugs to see if they are worth their high cost. Finally, Novartis is spending $2 billion on a new breast cancer drug, and a rare weight-gain disease linked to brain damage just got a newly approved treatment called Imcivree.

Source: statnews
URL: statnews.com/2026/03/20/chris-klomp-trumprx-high-dose-wegovy-readout-newsletter/?utm_campaign=rss (opens in new tab)